5:47 PM
 | 
Mar 11, 2016
 |  BC Extra  |  Clinical News

Alzheon planning AD Phase III

Alzheon Inc. (Framingham, Mass.) said it plans to start Phase III testing of ALZ-801 "in the near future" to treat mild to moderate Alzheimer's disease patients homozygous for apolipoprotein E epsilon 4 ( APOE4). ALZ-801 is an oral small molecule...

Read the full 194 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >